Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 12/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 11/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NQO2 | P16083 | 10/20 | 0.39 |
| ▸ | SUCNR1 | Q9BXA5 | 2/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.37 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.37 |
| ▸ | LDLR | P01130 | 1/20 | 0.37 |
| ▸ | ACACB | O00763 | 1/20 | 0.37 |
| ▸ | ACACA | Q13085 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4189864 | 0.83 | HDAC1 (0.46) | MTNR1AMTNR1BHDAC1 | |
| SCHEMBL4185804 | 0.82 | PDE4A (0.44) | TRPV1MEN1KMT2A | |
| SCHEMBL4184843 | 0.81 | MEN1 (0.40) | HDAC1MEN1KMT2ASUCNR1PRMT5 | |
| SCHEMBL13653102 | 0.81 | MEN1 (0.42) | HDAC1MEN1KMT2A | |
| SCHEMBL13653109 | 0.79 | PDE4A (0.39) | HDAC1MEN1KMT2APRMT5WDR77 | |
| SCHEMBL13653136 | 0.78 | CA12 (0.45) | TRPV1MEN1KMT2A | |
| SCHEMBL4184834 | 0.78 | GCGR (0.39) | HDAC1MEN1KMT2A | |
| SCHEMBL13653133 | 0.78 | PDE4A (0.42) | TRPV1MEN1KMT2A | |
| SCHEMBL13653122 | 0.76 | GCGR (0.37) | HDAC1MEN1KMT2APRMT5WDR77 | |
| SCHEMBL13653112 | 0.76 | GCGR (0.40) | HDAC1MEN1KMT2ASUCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247590-A1 | Indane amides | BAYER PHARMACEUTICLAS CORPORATION (US) | 2009-10-01 | — | — | US | disclosed |
| EP-1802577-A1 | INDANE AMIDES WITH ANTIPROLIFERATIVE ACTIVITY | Bayer Pharmaceuticals Corporation (US) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006062580-A1 | INDANE AMIDES WITH ANTIPROLIFERATIVE ACTIVITY | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247590-A1 | Indane amides | MKI67, PPIP5K2, CCNA1 | MTNR1A 1194/4885MTNR1B 1544/4885HDAC1 579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.